BioNTech SE is a biotechnology company focused on developing and providing transformative therapies for patients suffering from serious diseases
It is primarily known for its pioneering work in mRNA-based vaccines, particularly in the field of infectious diseases and cancer immunotherapy. By leveraging its proprietary technology platform, BioNTech aims to create personalized and innovative treatments that harness the body’s natural immune response. The company is committed to advancing scientific research and bringing novel therapeutics to market, working collaboratively with partners in the pharmaceutical industry and academic institutions to address unmet medical needs globally.
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQTSLA) and Palantir Technologies, Inc.
BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025.
Shares of BioNTech fell 4% on Monday. Vaccine stocks are volatile after Moderna's updated revenue guidance for 2025, which fell below analyst expectations.
All three major indices were red in Friday’s midday trading, with the S&P 500 and Nasdaq 100 down 1% and 1.24%, respectively, and on track for their worst weeks since September 2024.
MAINZ, Germany, February 24, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2024 on Monday, March 10, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (1:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
MAINZ, Germany, February 3, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today the completion of the acquisition of Biotheus (“Biotheus”), a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The acquisition was announced on November 2024 and builds on the successful collaboration on the late-stage clinical asset BNT327, an investigational bispecific antibody targeting PD-L1 and VEGF-A, and other bispecific antibody candidates.
Eleven large-cap stocks were the worst performers in the last week. Short positions announced for FTAI, revenue updates for MRNA, and price forecasts changed for GME, SNAP, RKLB, NTRA, LLY, ICLR, BNTX, NVO, and BMRN.
MAINZ, Germany, January 14, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today will present its 2025 strategic priorities and progress on the Company’s pipeline of mRNA therapeutics, immunomodulators, and targeted therapies at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California.
